AudiologyOnline Phone: 800-753-2160

Neuromonics, American Hearing Aid Associates Announce Reselling Agreement


Tinnitus company extends special pricing, support on devices that help ringing in the ears.

WESTMINSTER, Colo., April 3, 2014 – Professional audiologists, hearing aid dispensers, otolaryngologists, hospitals, and universities that belong to American Hearing Aid Associates (AHAA) will be able to help patients and customers suffering from tinnitus more than ever.

Under terms of a new agreement, AHAA will become a reselling partner of Neuromonics, Inc., manufacturer and distributor of clinically proven tinnitus treatment devices. Neuromonics will offer AHAA special pricing, marketing and other support for the Neuromonics Oasis™, Neuromonics Haven™ and Neuromonics Sanctuary™ products. The reselling  agreement is the first of its type for Neuromonics.

“The importance of reaching more tinnitus sufferers with effective treatment cannot be overstated,” says Eula Adams, CEO of Neuromonics. “Neuromonics’ agreement with AHAA is a tremendous step in providing greater access to relief for those with tinnitus.”

Tinnitus is the condition often described as buzzing, ringing, hissing, humming, roaring, whistling or “ringing in the ears” that someone hears in the absence of any external sound. Globally, tinnitus affects an estimated 10-15 percent of the population. In the United States alone, more than 50 million people suffer from the condition, according to the American Tinnitus Association. Usually brought on by exposure to loud noise, tinnitus is especially significant in the military, with more than 34 percent of returning veterans from Iraq and Afghanistan suffering from the condition.

Neuromonics products use calming, relaxing music embedded with a neural stimulus that interacts with the tinnitus perception, explains Adams. The music engages the auditory pathways to promote neural plastic changes. Over time, these changes help the brain to filter out the tinnitus perception, reducing tinnitus disturbance and providing long-term relief from symptoms. The compact devices are simple to use, function much like familiar consumer music players, and fit easily into patients’ lifestyles.

“While there is no tinnitus cure, so many individuals are seeking relief,” explains Tina Soika, president of AHAA. “The agreement with Neuromonics will help AHAA Associates deliver clinically proven devices and treatments for severe tinnitus sufferers as well as those needing on-demand relief.”

American Hearing Aid Associates (

American Hearing Aid Associates (AHAA) represents the nation’s highest-quality and most accessible hearing health care network, comprised of professional audiologists, hearing aid dispensers, otolaryngologists, hospitals, and universities across the country. AHAA aims to raise the quality of hearing health care throughout America by continual evaluation and upgrading of the educational standards and technical expertise of its hearing Associates.

Neuromonics, Inc. (

Based in Westminster, Colo., Neuromonics, Inc., manufactures and distributes clinically proven, FDA-cleared medical devices to treat tinnitus. The patented and clinically proven Oasis, working the Neuromonics Tinnitus Treatment, provides long-term treatment and significant relief for those with severe tinnitus. The Haven, with the ability to program and individualize hearing profiles, is a management tool offering situational relief for tinnitus symptoms. The Sanctuary, also a management tool, works with pre-programmed profiles for on-demand relief.

With research and development beginning in the early 1990s, Neuromonics has helped thousands of tinnitus sufferers improve their quality of life and overcome the daily life challenges associated with tinnitus. More than 400 licensed, trained audiologists across four continents administer the Neuromonics Tinnitus Treatment. Neuromonics news includes segments on national media including “The Doctors” and CNN.  You may also learn more about Neuromonics on the Neuromonics Expo Page on AudiologyOnline.

Congenital Cytomegalovirus (cCMV) Series | Earn up to 6 live hours!*

Our site uses cookies to improve your experience. By using our site, you agree to our Privacy Policy.